Podcasts about EHA

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.LymphomasDLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCTFL: Tisa-cel (ELARA), axi-cel (ZUMA-5)MZL: Liso-cel (TRANSCEND FL)MCL: Real-world outcomes post brexu-celCLL: Liso-cel (TRANSCEND CLL 004)Multiple MyelomaCilta-cel (CARTITUDE-1)Anito-cel (iMMagine-1)GC012FArlo-celBMS-986453TriPRIL Presenters:Brad Kahl, MDProfessor of MedicineWashington University St Louis, MissouriNoopur Raje, MD Director, Center for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program: https://bit.ly/3ViR62V

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).Key Clinical Trials Discussed1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL7. Additional Studies Mentioned:R-Pola-Glo Frail StudyDLBCL Classification

June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings.Read our conference round-ups here:EHA: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00206-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhaeICML: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00207-8/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhaeISTH: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00209-1/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trial Presenters:James Davis, PharmD, BCOPClinical Pharmacy Specialist, Malignant HematologyMUSC Hollings Cancer CenterAssistant ProfessorMUSC College of PharmacyCharleston, South CarolinaVictoria Nachar, PharmD, BCOPClinical Pharmacist Specialist, HematologyUniversity of Michigan Rogel Cancer CenterAnn Arbor, MichiganLink to full program: https://bit.ly/3H2EcSX

Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline triplet vs. quadruplet studies, real-world referral trends, CARTITUDE-4 subgroup outcomes, and the expanding utility of bispecifics and trispecific antibodies, particularly for extramedullary disease. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.   Timestamps: 2:14: Memorable career experiences for Claudio   4:20 Biggest breakthrough in MM  5:10 Interest in plasma cell disorders  6:30 A surprising fact about multiple myeloma  7:40 Claudio's top choice for a dinner party guest  10:30 The importance of MRD in haematology  13:00 Monoclonal antibodies and CAR-T therapies  19:00 Current challenges  22:22 Claudio's key EHA and ASCO takeaways  28:30 Claudio's three magic wishes  

La Dra. Claudia Agudelo, hematóloga adscrita a la Fundación Santa Fe en Bogotá, Colombia, nos habla sobre los estudios más relevantes del Congreso Anual de la Asociación Europea de Hematología 2025 celebrado en Milán, Italia.Los trabajos comentados son:ALLG BM12 CAST (abstract S103)JNJ-90014496 (abstract S239)AMLSG 21-13 (abstract S149)BRUIN CLL-321 (abstract PS2282)AXI-CEL (real-world study) (abstract S237)Referencias:Curtis D., Purtill D., Lewis C., y cols. (S103) A phase 3 randomised trial of post-transplant cyclophosphamide for gvhd prophylaxis in  matched sibling donor peripheral blood stem cell transplantation: the ALLG BM 12 cast trial.Patel K., Rhodes J., Mounljoy L., y cols. (S239) A global phase 1b study of jnj-90014496, a cd19/cd20 bi-specific chimeric antigen receptor  (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large b-cell lymphoma (LBCL).Döhner H., Weber D., Saadati M., y cols. (S149) Phase 3 study of intensive chemotherapy with or without dasatinib in patients with core binding factor acute myeloid leukemia – final analysis of the AMLSG 21-13 trial.Ghia P., Rossi D., Ferrant E., y cols. (PS2282) Patient reported outcomes from BRUIN CLL-321: a randomized phase 3 trial comparing pirtobrutinib to idelalisib/rituximab or bendamustine/rituximab in covalent BTKi pretreated CLL/SLL.Lee D., Kambhampati S., Bobillo M. S., y cols. (S237) Real-World effectiveness and safety outcomes among key subgroups of second-line (2L) axicabtagene ciloleucel (axi-cel) for patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL).Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. EHA® es una marca registrada de la European Hematology Association.Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

On this week's episode, Josh Schimmer, Paul Matteis, Eric Schmidt and Yaron Werber kick off with an optimistic view of the current biotech state of affairs, citing the FDA is open for business, we're seeing companies successfully launch and M&A is happening, though the Trump Administration's Most Favored Nation plan still looms. In regulatory news, UroGen's FDA approval of Zusduri for tumor ablation in recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer was seen as a sign the FDA is continuing to be flexible and business as usual. Where it's not business as usual, concerns were raised about RFK Jr.'s dismantling of the ACIP and worry for the future of vaccine practices. With a continued amount of investor activism against boards, the group opined on ADAR1's letter to Keros' board and Deep Track's battle with Dynavax. The group shared some excitement around the emerging field of psychedelics, including a bullish perspective on Compass Pathways' upcoming data readout. The conversation shifts to questions about biotech's current focus on M&A versus building large companies. The episode concludes with EULAR and EHA conference updates and the favorable data sets coming out of those meetings, leading to a discussion on what's holding CAR-T valuations back in the I&I space. *This episode aired on June 13, 2025.

Recorded on 12 June 2025 for ICMDA Webinars.Dr Peter Saunders chairs a webinar with Dr Mathew GeorgeThe Kingdom of God is a foundational concept in Christian theology, deeply rooted in the teachings and ministry of Jesus Christ. While traditionally associated with spiritual and eschatological dimensions, its relevance extends into every sphere of life—including healthcare.The values and vision of the Kingdom offer a transformative framework for how care is delivered, how patients are treated, and how justice and compassion are integrated into medical practice.This webinar explores the understanding of the Kingdom of God, its theological significance, its implications for healthcare, and how it can be practically applied in contemporary clinical settings.Dr Mathew is a dentist by profession and served at Duncan Hospital in Bihar (1993–2013), a unit of Emmanuel Hospital Association (EHA). With his wife, Latha, also a dentist, he pioneered dental work in EHA, establishing 14 dental units as Coordinator of Oral Health Services and later serving as Managing Director.From 2013–2019, he led the Missions Department at EMFI, shaping healthcare mission programmes. Currently, he heads Companions of Grace International, empowering healthcare professionals for mission work. Passionate about teaching and mentoring, he has spoken globally for 30 years.⁠To listen live to future ICMDA webinars visit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://icmda.net/resources/webinars/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Send us a textH.E. Dr. Ahmed El-Sobky, Ph.D. is Chairman of the Egypt Healthcare Authority ( EHA - https://eha.gov.eg/en/about-eha/ ) and a prominent figure esteemed for his visionary leadership and expertise across clinical and managerial domains. As the Chairman of the EHA since 2020, Dr. El-Sobky has founded the guiding principles of the organization and led transformative measures to enhance healthcare services and accessibility nationwide. Dr. El-Sobky's contributions extend globally as a Member of the UHC2030 Steering Committee and a Governing Council member in the International Hospital Federation, as well as at the Ministry of Health and Population ( MOHP - https://www.mohp.gov.eg/ ), where he supervises critical projects like the Hayah Karima Project ( https://hayakarima.com/en/about-us ) and the Universal Health Insurance Project, leveraging his insights to drive impactful change.Dr. El-Sobky's career in health strategic management started early in 2015 being the youngest assistant, then Deputy Minister of Health and Population for Monitoring and Follow-up affairs, underscoring his dedication to advancing public health locally and globally. Dr. El-Sobky's academic journey is marked by a Ph.D. in Diagnostic Radiology from Menoufia University, Master of Science in Clinical Service Operations from Harvard Medical School, an Executive Diploma in Public-Private Partnership in Healthcare from the Frankfurt School of Finance & Management, and an MBA in Business Administration and Management from Ecole Supérieure Libre des Sciences Commerciales Appliquées.Dr. El-Sobky also chairs the scientific council of the Egyptian board of healthcare management, a position he has held since 2021.#Egypt #AhmedElSobky #EgyptHealthcareAuthority #UniversalHealthInsurance #DiagnosticRadiology #BigData #NewLibraryOfAlexandria #MinistryOfHealthAndPopulation #SustainableDevelopmentGoals #AbdelFattahAlSisi #HepatitisC #HealthcareInformationAndManagementSystemsSociety #Aging #AntimicrobialResistance #Cairo #HayaKarima #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us a textWelcome to The Helicopter Podcast, brought to you by Vertical HeliCASTS!Host Halsey Schider engages in a compelling conversation with Fredrik Kämpfe, chair of the European Helicopter Association (EHA). Fredrik shares insights into the collaborative efforts between EHA and the European Rotors event, highlighting their joint mission to advocate for and advance the European helicopter industry.Fredrik outlines his role within EHA, emphasizing the organization's dedication to representing the helicopter community across 13 European countries. He discusses EHA's proactive engagement with operators and the European Union Aviation Safety Agency (EASA) to address key industry challenges, including regulatory developments, safety enhancements, and sustainability initiatives. Under Fredrik's leadership, EHA has been instrumental in organizing events like European Rotors, which serve as platforms for industry stakeholders to collaborate, share knowledge, and showcase innovations. These efforts aim to foster a unified and progressive rotorcraft community in Europe. Tune in to this insightful episode to learn more about EHA's initiatives and Fredrik's vision for the future of the European helicopter industry.Thank you to our sponsors Vertical Aviation International, Robinson Helicopters and Sellacopter.

In this episode of Hema Now, Dr. Jonathan Sackier welcomes Professor Antonio Almeida, a leader in hematology and the 2024 President of the EHA. They delve into the highlights from this year's EHA Congress, discuss the founding of the Católica Medical School, and explore the transformative role of AI in healthcare.   Timestamps:  (00:00) -Introduction  (01:40) -Reflection on the EHA 2024 Congress  (06:10) -Approaches for future congresses  (10:30) -Proudest accomplishments and EHA education initiatives   (17:00) -Reflections on the treatment landscape of blood-related conditions   (26:00) -Importance of registries in uncovering more about these diseases  (30:10) -Potential of AI in hematology  (32:50) -Role of public policy in shaping the future of hematology  (37:00) -What drove Antonio to found a medical school  (40:00) -Antonio's three wishes 

Legendary Melvins drummer Dale Crover is back on the show and this time he's bringing some friends! AAL and EHA of Low Flying Hawks are making their podcast debut to celebrate two new albums: Low Flying Hawks' Makebelieve coming out October 25 and Dale Crover's awesome new solo album Glossolalia, out now! In our chat, we talk about the writing process for the latest LFH album, the residual affects of the pandemic that still linger for artists, taking two years to create the album this time around, and the idea that mystique brought something tangible to music and artists. Then we sequel over to Dale Crover's awesome guests that he got on his latest solo record, the story of how he got Tom Waits to say “yes” to being a part of the title track, him opening as a DJ on the upcoming Red Kross European run, and the pros of modern music recording compared to the time crunch the Melvins had early on. Petar and Sylvia discuss Kerry King's answer in who he thinks can portray him in a Slayer biopic film, Sick New World coming back to Vegas and bringing an Acid Bath reunion with it, just accepting their would never be an Acid Bath reunion years ago to our surprise, Jake E. Lee getting shot while walking his dog, and Deftones setting a record with there demo tape on Discogs. Song: Low Flying Hawks “Suspension of Disbelief” Song: Low Flying Hawks “Out for Blood” Song: Dale Crover “I Quit” Featuring Kim Thayil of Soundgarden Learn more about your ad choices. Visit podcastchoices.com/adchoices

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.    Credit available for this activity expires: 07/31/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001409 ?ecd=bdc_podcast_libsyn_mscpedu

Today's VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH,... The post Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs appeared first on VJHemOnc.

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the... The post The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 appeared first on VJHemOnc.

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib Program faculty:Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Resources:To download the slides associated with this podcast discussion, please visit the program page.

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted... The post Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 appeared first on VJHemOnc.

Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions 4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers 5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars 6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars 7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability 8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCLhttps://library.ehaweb.org/eha/2024/eha2024-congress/4136516 2.     Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):https://library.ehaweb.org/eha/2024/eha2024-congress/422343 3.     3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740 4.     ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515 5.     HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext 6.     Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268 7.      Single-agent epcoritamab in Richter's transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the  EHA 2024 Congress including:COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDSReal-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practicePhase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDSPhase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis Program faculty:Courtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisEunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkResources:To download the slides associated with this podcast discussion, please visit the program page.

On this week's Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt, Sam Fazeli, Bruce Booth and Grace Colon discuss the big news of the week including the FDA granting a landmark expanded approval for Sarepta's Elevidys for patients with Duchenne Muscular Dystrophy. The hosts share their varying opinions on whether the expanded approval was the right decision. The group also engages in a few discussion topics around management, including the “everything is awesome CEO” and the best and worst practices for managing a board. With multiple companies dealing with a stock drop this week (Cabaletta Bio, Kyverna Therapeutics, Taysha Gene Therapies, Aerovate Therapeutics, Ovid Therapeutics), the hosts discuss the different issues these pose for management teams and how to deal with market reactions. The group also shares thoughts on the 2024 class of IPOs, EHA 2024 highlights, BioNTech's clinical hold on its early-stage cancer drug study, and much more. This episode aired on June 21, 2024.

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter's... The post Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more appeared first on VJHemOnc.

Guest speaker “Angus” Shipo Xie of Hankun Law joins Brian Yang to discuss new overseas data transfer rules, while Dexter Yan explains China biotechs' Hutchmed, Jiangsu Hengrui and Innovbent Bio's clinical data readouts at the recent EHA and ADA annual meetings. https://scrip.citeline.com/SC150487/China-Biotech-Podcast-EHAADA Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the EHA 2024 Hybrid Congress, June 13-16, Madrid, Spain.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025FACULTYCindy Neunert, MDAssociate Professor of PediatricsColumbia University Irving Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcasts-in-pediatric-itp-advancements-in-pediatric-itp-management-insights-from-eha-2024

In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024! How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today? And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

Clara Camaschella"La donna del ferro"Neos Edizioniwww.neosedizioni.it“Sono considerata una delle rare donne che hanno fatto carriera in medicina alla fine degli anni Novanta”.Così inizia il racconto di Clara Camaschella. Dalla Valsesia degli anni Sessanta alla Facoltà di Medicina di Torino negli anni Settanta e, dopo una borsa di studio oltreoceano, una lunga, prestigiosa, ma molto faticosa e complessa carriera scientifica alla scoperta dei misteri del sangue e… del ferro. L'autobiografia di Clara Camaschella è un racconto di vita e lavoro dove, con ironia e leggerezza e un linguaggio schietto ma rigoroso, si affrontano anche tematiche complesse (il superamento di un handicap, la malattia), in particolare le difficoltà delle donne ad affermarsi negli ambienti universitari a causa del maschilismo. Clara Camaschella cresce in un mondo provinciale fatto di religione, suore, colonie estive e Azione Cattolica. Al liceo confida al suo diario le paure e la voglia di prendere in mano il proprio futuro La scelta della Medicina, all'Università di Torino, le fa scoprire un mondo nuovo i cui orizzonti si amplieranno ulteriormente durante uno stage negli Stati Uniti condiviso con colui che diventerà suo marito. Nel 1991 all'Ospedale San Luigi di Orbassano, secondo polo didattico dell'Università di Torino, inizia ad occuparsi della genetica molecolare dell'emocromatosi (“È stato l'inizio di un'avventura molto bella che ha portato a capire la fisiologia del metabolismo del ferro e la sua sregolazione nelle malattie”). La sua carriera, prima a Torino poi a Milano, sarà una corsa ad ostacoli (“Quando il Consiglio di Facoltà si restringeva ai soli professori ordinari noi donne rappresentavamo sempre uno sparuto gruppetto, al san Raffaele ci si poteva contare sulle dita di una mano!). Ordinaria di Medicina Interna all'Università di Torino, dal 2004 ha ricoperto lo stesso ruolo all'Università Vita Salute San Raffaele di Milano, passando da un'attività prevalentemente clinica alla ricerca scientifica. “L'importante è chiedere molto a noi stessi indipendentemente dai risultati”: il mantra che le è stato ripetuto più volte è diventato regola di vita, consentendole di diventare figura di prestigio in ambito medico scientifico internazionale per le sue ricerche sul metabolismo e le patologie del ferro. Ha coordinato con successo due gruppi di ricerca, prima a Torino, poi a Milano. Grazie ai risultati e alle collaborazioni ha ottenuto premi prestigiosi, è stata Presidente della Società Internazionale per lo studio del ferro in Biologia e Medicina (BioIron), membro del board di riviste internazionali e di società scientifiche sia in Europa, sia negli Stati Uniti. “Nel caso di cariche elettive ho battuto uomini che consideravo molto più capaci di me, purtroppo sempre con il sospetto di aver vinto solo perché donna”. Clara Camaschella, nata a Varallo nel 1948, dopo la maturità classica si è laureata in Medicina a Torino e poi specializzata in Medicina Interna e in Ematologia. Una carriera legata a Torino dove ha svolto attività clinica alle Molinette e al San Luigi di Orbassano. Ordinaria di Medicina Interna dal 2000, dal 2004 ha ricoperto lo stesso ruolo all'Università Vita Salute San Raffaele di Milano. Responsabile di una Unità di Ricerca sul metabolismo del ferro è stata vicedirettrice della Divisione Genetica e Biologia Cellulare dell'IRCCS Ospedale San Raffaele. Autrice di duecentottanta pubblicazioni scientifiche e collaborazioni a testi internazionali, ha fatto parte del Board della società di Ematologia americana ASH e dell'europea EHA e Presidente della Società Internazionale per lo studio del ferro BioIron. Ha ricevuto premi scientifici come la Ham Wasserman lecture e il Jean Bernard life time achievement award Sposata con Federico Caligaris Cappio, dopo molti anni a Torino, ora vive a San Felice di Segrate (Milano). IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

After a 5 minute score by Nathaniel Finch, David Eha recaps some college basketball action. Eha covers Ball State for the Ball State Network, and the Cardinals won 76-67 over Western Michigan. Tanner Camp of The Region Radio Sports Network joins Coach to talk about Marquette Catholic's win over Triton. Kurt Darling of Nine Star TV calls in to recap some more boys basketball. Darling gives a rundown of the Tipton 60-46 win over Shenandoah. Dave Sockel of Southern Indiana Sports Productions turns the focus back on Girls' Sectionals. He covered the Bedford North Lawrence 43-39 win over Jennings County. Kenny Kramer from LVH1 calls in and recaps LaVille's 47-37 win over North Judson. Andrew Smith of the New Pal Radio Network joins Coach to talk about Mt. Vernon's 48-39 win over New Palestine. Len Clark of Irish101.com calls to recap Notre Dame's rough loss to Pitt. The final score for that game was 70-60. Coach Kyle Brummett of Wabash joins to talk about his team's 89-81 win over Denison University. See omnystudio.com/listener for privacy information.

Robb Hansen is in-studio to talk with us about the Emmanuel Hospital Association, a medical ministry that serves the marginalized in North India. Rob voluntarily leads EHA (USA) which exists to support the work of EHA in India through a growing network of churches and individuals who partner through the U.S. office to provide prayer and financial support. See omnystudio.com/listener for privacy information.

Jonathan is joined by Elizabeth Macintyre, President-Elect and Board Member of the Biomedical Alliance, Europe; and Past President of the European Haematology Association (EHA). The pair delve into the world of haematology, focusing on Macintyre's research towards equal access, haematological diagnostics, and her presidency during the COVID-19 pandemic.  Use the following timestamps to navigate the content in this episode:  (00:00)-Introduction  (01:39)-Macintyre's route into medicine   (04:13)-Haematology in Europe, and leading the EHA   (08:30)-Diagnostics in haematological malignancies  (10:18)-Changes to congress following COVID-19  (14:12)-Coffee conversations   (15:36)-Madrid 2024  (18:42)-Jonathan speaks French   (24:07)-Medical politics and economics  (30:00)-Accessing new treatments   (35:43)-Three wishes for the future of healthcare  

Jonathan is joined by António Almeida, President of the European Hematology Association (EHA); and Professor and Director of the Clinical Haematology Service, Hospital da Luz, Lisbon, Portugal, to discuss his highlights since becoming EHA President. The pair cover the three pillars of EHA, the anticipated topics for the 2024 congress, and how Almeida has implemented a brand-new medical school, as well as much more.    Use the following timestamps to navigate the content in this episode: (00.00)-Introduction (01:55)-Almeida's new medical school (03:35)-EHA Master Class peer-based learning and modern medical education (09:00)-Presidential highlights  (11:50)-EHA's three pillars in the coming year (16:05)-EHA 2024 in Madrid (20:15)-Research in myeloproliferative and myelodysplastic syndromes (23:00)-Clinical trial updates in myelodysplastic syndromes and chronic myeloid leukaemia (26:50)-Changes over the course of Almeida's career (31:30)-Treatment advances on the horizon (32:50)-CRISPR to treat sickle cell disease and β-thalassaemia (36:30)-Three wishes for the future of healthcare 

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.Here are the shownotes:1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutationhttps://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext 4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupshttps://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction 5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyhttps://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs 7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLhttps://www.nejm.org/doi/full/10.1056/nejmoa1902688 8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023. 10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email

Welcome to a new episode of the Natural Beauty Podcast, where the host Satu Mäkinen talks with Eha Urbsalu – the founder of the award-nominated Estonian natural cosmetics brand Viking Beauty Secrets.In the episode, Eha shares more about the Exfoliating Face Scrub, which is nominated for the European Natural Beauty Awards this year 2023.We also talk about how Viking Beauty Secrets is making efforts towards a cleaner environment and how Eha thinks the cosmetics industry will look like going into the future.You can follow Viking Beauty Secrets on social media, such as Instagram, and learn more about the brand's products on their website at vikingbeauty.eu.Natural Beauty Podcast is powered by the Nordic & European Natural Beauty Awards. By following the Natural Beauty Podcast, you will stay updated with the highlights from both awards.To learn more about the European Natural Beauty Awards, such as about the freshly nominated European edition cosmetics, jump to europeannaturalbeautyawards.com.Get to know all the previously awarded cosmetics of the Nordic Natural Beauty Awards, and learn more about the Nordic edition at nordicnaturalbeautyawards.com.Join the conversation on our social media channels; Nordic Natural Beauty journey on Instagram, European Natural Beauty journey on Instagram, and all the initiatives' common journey on LinkedIn.To stay updated on all news, make sure you have subscribed to this podcast and Natural Beauty Awards's newsletter.Disclaimer: This podcast is for entertaining and educational purposes only. If you have health concerns, seek professional medical advice.(Music by Wataboi from Pixabay.)

Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials,  CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more.  Thanks to our episode sponsor, Karyopharm.

Drs. Masarova and Mesa discuss myelofibrosis data presented during the 2023 annual meeting of the European Hematology Association.

The Trader Joe's recall situation has garnered significant attention in the past few weeks, as the popular retail chain declared three different product recalls during the last week of July. In this episode of the Xtalks Food Podcast, Sydney talks about the details of the recall, which has raised some eyebrows with food safety. Trader Joe's, in a statement to Vox, called the series of recalls “a coincidence.” Yet, Melvin Kramer, President of the EHA environmental and public health consulting group, suggests another theory. The unique appeal of Trader Joe's to consumers lies in its blend of global and local foods produced by small-scale makers. This variety may increase Trader Joe's recall risk compared to stores sourcing from large-scale manufacturers. Trader Joe's has gained a cult-like following for selling a variety of local specialty foods and crafting engaging narratives about its brands; however, the recent increase in Trader Joe's recall from once or twice a month to three times in a week is alarming. The team talks about the lack of oversight from federal authorities like the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) and wonder whether consumers are partially to blame for high demand.Also in this episode, Sydney reviews Netflix's new food safety documentary, “Poisoned: The Dirty Truth About Your Food.” The objective of the documentary is not to dictate what foods the audience should avoid due to health concerns or to debunk myths about so-called healthy foods. Rather, its primary focus is to shed light on the negligent food safety practices employed by various companies and federal authorities. The film unpacks a variety of food safety issues, starting with the notorious E. coli outbreak between 1992 and 1993 that claimed the lives of four children who had eaten contaminated burgers from the fast-food chain Jack in the Box. The film also profiled Kenneth Kendrick, a former plant manager at Peanut Corporation of America who blew the whistle on his boss, corporation owner Stewart Parnell, for tampering with inspection records to ship out contaminated nuts. The narrative unfolds through several viewpoints, including those of food industry attorneys, politicians, regulators, scientists, victims' parents and implicated businesses. The team praises the documentary for shedding light on several important but overlooked food safety issues in the US.Read the full article here:Trader Joe's Recall 2023: Multiple Products Under the MicroscopeNew Netflix Food Documentary Exposes America's Faulty Food Safety SystemFor more food and beverage industry content, visit the Xtalks Vitals homepage.Follow Us on Social Media Twitter: @XtalksFood Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLLSEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLLCAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphomaPhase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLLBRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLLPresenters:Catherine C. Coombs, MD, MSAssociate Clinical ProfessorDivision of Hematology/Oncology, Department of MedicineUCI HealthOrange, CaliforniaToby Eyre, MBChB, MDHonorary Senior LecturerHematology and CancerUniversity of OxfordConsultant HematologistDepartment of HematologyHematology and Cancer Centre, Oxford University Hospitals NHS Foundation TrustOxford, United Kingdom 

Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent... The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.

Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent... The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.

This week we're joined by Gillian Campbell, the Communications and Public Affairs Lead at Existing Homes Alliance Scotland, a professional with a wealth of experience in the housing sector.Gillian has been involved in some really interesting work around influencing government policy around their retrofit strategy. In particular, their research has revealed insights that are relevant to anyone in the retrofit sector: from the need for good messaging, to the importance of timing in using it, and the fundamental need for frameworks that support and enable consumers to act. Whether the audience is a homeowner or asset manage, in Scotland or North America, the lessons are largely relevant to all. Notes from the episodeThe Existing Homes Alliance ScotlandBuilding blocks for successful customer journeys to net zero homes – EHA Policy PaperOwning the Future: a framework of regulations for decarbonising owner-occupied homes in Scotland – Report for the EHA by Dr Catrin Maby and Louise SunderlandAffordable Warmth – Next steps for clean heat in Scotland – Report by WWF ScotlandThe Novoville platform we mentioned**SOME SELF-PROMOTING CALLS TO ACTION**We don't actually earn anything from this, and it's quite a lot of work, so we have to promote the day jobs.Zero Ambitions Partners email address - zap@eiux.agencySubscribe and advertise with Passive House Plus (UK edition here too)Join ACANJoin the AECB Join the IGBCListen to Accelerate to Zero, Sara's podcast produced at BE-ST, on Apple or Spotify Email Alex and Dan about websites, branding, and communications - zap@eiux.agency; Everything is User Experience**END OF SELF-PROMOTING CALLS TO ACTION**

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients... The post Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice appeared first on VJHemOnc.

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients... The post Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice appeared first on VJHemOnc.

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf92. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma: https://pubmed.ncbi.nlm.nih.gov/36690811/4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma: https://pubmed.ncbi.nlm.nih.gov/36413381/ 

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and... The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and... The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.

Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359 Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN) https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2 https://ash.confex.com/ash/2022/webprogram/Paper157126.html ALFA-0701. The addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukemiahttps://www.thelancet.com/article/S0140-6736(12)60485-1/fulltext Quizartinib data presented at EHA 2022 https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676 International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemiashttps://ashpublications.org/blood/article/140/11/1200/485730/International-Consensus-Classification-of-Myeloid The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasmshttps://www.nature.com/articles/s41375-022-01613-1  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.77.6112?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remissionhttps://www.nejm.org/doi/full/10.1056/NEJMoa2004444

Myeloma advancements are happening quickly. Learn more from Paul Richardson, MD of the Dana Farber Cancer Institute about the latest findings from two key summer conferences.  Thanks to our episode sponsor, Glaxo Smith Kline